Introduction
In aortic stenosis, a decrease in the aortic valve area progressively occurs, which generates a restriction in left ventricle (LV) blood outflow to the aorta. The most common causes are degenerative, rheumatic and congenital. Degenerative aortic stenosis occurs in 5% of adults older than 65 years, out of which 11% have severe aortic stenosis. It is considered "severe" when the aortic valve orifice is smaller than 1 cm 2 and mean aortic transvalvular gradient is equal to or higher than 40 mmHg.
Patients with severe aortic stenosis are initially asymptomatic; however, in the course of the pathology they develop dyspnea, angina and syncope, which cause quality of life deterioration and increased mortality [1] [2] [3] [4] [5] . One-year risk of sudden death in asymptomatic patients is 1%, and in symptomatic individuals this risk increases to 3-5% at six months. Aortic valve replacement surgery has been shown to achieve a significant mortality reduction in these patients [5] [6] [7] . In patients with contraindication or high risk for aortic valve replacement surgery, percutaneous aortic valve prosthesis implantation is a safe and effective alternative.
Thus, severe aortic stenosis is a high-risk condition, which requires interdisciplinary management to reduce morbidity and mortality. The Clinical Practice Guidelines, Drug Safety Monitoring and Techno-surveillance Directorate of the Institute for Health Technologies Evaluation and Research (IETSI -Instituto de Evaluación de Tecnologías en Salud e Investigación), together with specialists of the National Cardiovascular Institute (INCOR -Instituto Nacional Cardiovascular) and the Peruvian Social Security (EsSalud), developed these evidence-based clinical practice guidelines (CPG), which issued recommendations and good clinical practice (GCP) points for the evaluation and treatment of patients with severe aortic stenosis. The present article is a summary of said CPG.
Methodology
The procedure followed for the development of these CPGs is described in detail on its extended version, which can be downloaded from the EsSalud IETSI website (http://www.essalud.gob.pe/ietsi/guias_pract_clini.html).
In brief, the following methodology was applied: -Formation of the local guideline development group (Local GDG). It was comprised by methodologists and cardiology, interventional cardiology and cardiovascular surgery specialist physicians. -Formulation of questions. In accordance with this CPGs' objectives and scope, the Local GDG formulated seven clinical questions ( document (through a systematic search of CPGs on the subject) (Appendix 1). When SRs of acceptable quality were found, one was chosen for decision making, which was updated when the local GDG considered it necessary. When no RS of acceptable quality was found, a new search was made for primary studies. -Quality of evidence evaluation. Quality of evidence for each outcome of each PICO question was considered high, moderate, low or very low (Table 2) . To assess the quality of evidence, the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was followed 8 and GRADE evidence profile tables were used (Appendix 2). Finally, the PICO question was assigned the lowest level of quality reached by any of these outcomes. -Formulation of recommendations. The local GDG reviewed the selected evidence for each clinical question in periodic meetings and issued strong or weak recommendations (Table 2 ) using the GRADE methodology 9 . For this, the following was considered: 1) benefits and harms of the options; 2) patient values and preferences; 3) acceptability by health professionals; 4) feasibility of the options at EsSalud health establishments, and 5) use of resources. After discussing these criteria for each question, the local GDG formulated recommendations by consensus or by simple majority. In addition, the local GDG formulated GCP points, usually based on clinical experience. -Review by external experts. The present CPGs were reviewed in meetings with specialist physician representatives of other institutions and decision-makers.
Furthermore, the extended version was electronically submitted to external experts (mentioned in the acknowledgments section) for its review. The local GDG took the results of these reviews into account for amending the final recommendations. -CPG approval. These CPGs were approved to be uses in EsSalud, with Resolution No. 47 -IETSI -ES-SALUD -2018. -CPG updating. This GPC has a validity of three years. As the end of this period approaches, a literature SR will be carried out for its update, after which it will be decided whether this CPG is updated or if a new version is created.
Recommendations
The present CPG addressed seven clinical questions, related to two subjects: severe aortic stenosis initial evaluation and treatment. Based on these questions, nine recommendations were formulated (one strong recommendation and eight weak recommendations), 16 good clinical practice points and a flow chart (Table 3 and Fig. 1 ).
In patients with aortic stenosis, the physician should decide which criteria will be used to establish the severe aortic stenosis diagnosis (question 1). Then, the physician should decide on treatment, and for that he/ she must determine which surgical risk grading system will be used (question 2), how will he/she treat asymptomatic patients (question 3) and when will he/she choose surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR) in symptomatic patients (question 4). If performing a TAVR is decided, the access route must be decided (question 5) and the possibility of carrying out or not a percutaneous coronary intervention if the patient also has severe coronary artery disease (question 6). Finally, for the management of patients with severe aortic stenosis, it is necessary to determine if a group of experts or Heart Team will be required (question 7). Below, the recommendations for each clinical question, as well as a summary of the rationale to arrive to each recommendation, are presented. Question 1. In patients with aortic stenosis, which severity classification system should be used?
Recommendations and good clinical practice points
To classify aortic stenosis-diagnosed patients into mild, moderate or severe aortic stenosis, using the aortic stenosis classification system proposed by the American Heart Association/American College of Cardiology (AHA/ACC) 2014 guidelines (not modified in the 2017 update) is recommended. GCP.
From evidence to decision
Severity should be determined in all patients with aortic stenosis. This classification has prognostic and therapeutic implications. In patients with mild or moderate aortic stenosis, clinical observation and periodic monitoring shall be carried out. In those with severe symptomatic aortic stenosis, valve replacement shall be evaluated. 
Good clinical practice approach
By consensus, the AHA/ACC 2014 classification system was chosen 11 (Table 4) The local GDG believes that all or nearly all professionals that review available evidence would follow this recommendation. In the recommendation formulation, the term "recommended" is used Weak recommendation (for or against)
The local GDG believes that most professionals that review available evidence would follow this recommendation, but a group of professionals might not follow it. In the recommendation formulation, the term "suggested" is used.
Local GDG: Local guideline developing group. Patients with severe aortic stenosis shall be classified according to their surgical risk as: -Low risk. STS or EuroSCORE II < 4%, without frailty or comorbidities and with no hindrances for the specific procedure -Intermediate risk. STS or EuroSCORE II between 4 and 8%, with no more than slight frailty or compromise of no more than one major organ/system that will not improve postoperatively, and minimum hindrances for the specific procedure -High risk. STS or EuroSCORE II > 8%, or with moderate to severe frailty, with compromise of no more than 2 major organs/systems that will not improve postoperatively, or a possible hindrance to the specific procedure -Prohibitive risk. Preoperative one-year mortality and morbidity risk > 50%, with compromise of ≥ 3 major organs/systems that will not improve postoperatively, severe frailty, or a severe hindrance to the specific procedure In patients with severe symptomatic aortic stenosis with life expectancy of more than one year, aortic valve replacement should be performed
GCP
In patients with severe symptomatic aortic stenosis with life expectancy of more than one year and low surgical risk, we suggest SAVR performance as first treatment choice 4 and 8%, with no more than slight frailty or compromise of no more than one major organ/system that will not improve postoperatively and minimum hindrances to the specific procedure.
• High risk. STS or EuroSCORE II > 8% or with moderate to severe frailty, with compromise of no more than two major organs/systems that will not improve postoperatively or possible hindrance to the specific procedure.
• Prohibitive risk. Preoperative mortality and morbidity risk > 50% at one year, with compromise of three or more major organs/systems that will not improve postoperatively, severe frailty or severe hindrance to the specific procedure. GCP
From evidence to decision
Patients with severe aortic stenosis require aortic valve replacement treatment, and it is therefore necessary for surgical risk to be assessed in these patients. The most widespread and known surgical risk scoring systems are EuroSCORE II 16 and STS 17 . Both predict mortality and morbidity risk after valve replacement surgery. EuroSCORE II is available at www.euroscore. org and STS at http://riskcalc.sts.org/stswebriskcalc/#/ calculate To answer this question, three subpopulations were assessed: patients intervened with SAVR, patients operated with TAVR and patients who were operated with either intervention indistinctly. SRs of observational studies for each subpopulation were found. In patients undergoing SAVR, one SR (5 studies, n = 11,791) concluded that STS overestimates mortality 18 . In patients undergoing TAVR, one SR (24 studies, n = 12,346) concluded that EuroSCORE II underestimates mortality 19 . In patients undergoing SAVR or TAVR, one SR (10 studies, n = 13,856) concluded that STS overestimates mortality 18 .
Owing to these heterogeneous results, making a recommendation in favor of applying both scoring systems for making the decision on which intervention to perform was decided. Given that the quality of evidence is very low and that not all doctors would accept such a measure, and neither would patients do, since it would imply a larger number of evaluations and time, assigning a weak strength of recommendation was decided.
Good clinical practice approach
Using the cutoff points proposed by the Singh meta-analysis (2017) 20 and the ESC/EACTS 2017 12 guidelines was decided to classify patients with severe aortic stenosis at low risk (< 4%), intermediate risk (4-8%) and high risk (> 8%), both with STS and with EuroSCORE II 21, 22 . Finally, adopting the consensus recommendation of the ACC 23 experts was decided in order to include other criteria such as frailty, comorbidities and hindrances to the specific procedure. • Adverse hemodynamic changes (symptoms or blood pressure decrease) during stress testing.
• Severe pulmonary hypertension with no other explanation. GCP. -Patients with severe asymptomatic aortic stenosis should be clinically evaluated every six months or when the patient experiences symptoms related to the disease (dyspnea, angina or syncope). GCP.
-Patients with severe asymptomatic aortic stenosis that start developing symptoms will be assessed for risk stratification and aortic valve replacement scheduling. GCP.
From evidence to decision
A patient with severe asymptomatic aortic stenosis is defined as a patient who does not report symptoms 24 . Approximately more than half the patients with severe aortic stenosis are asymptomatic at diagnosis 6 . Treatment of these patients is controversial.
One SR 25 (4 observational studies, n = 1,300) compared early aortic valve replacement versus conservative treatment and reported similar all-cause mortality or cardiovascular cause mortality. This would indicate that the short-term benefit of performing early interventions in this group of patients is probably small. However, the lack of randomized clinical trials (RCTs) 26 hinders clearly establishing the potential benefit of early intervention.
A potential benefit of early intervention could be the delay in symptom onset and the possibility of definitive treatment in patients who cannot return for consultation. In our institution, availability of surgery shifts for aortic valve replacement is limited, and this intervention should therefore be carried out in patients with severe symptomatic aortic stenosis, since they are at higher mortality risk than those who are asymptomatic. Therefore, formulating a recommendation against systematically practicing early aortic valve replacement was decided. Given that the quality of evidence is very low, that patient acceptability is low because they are asymptomatic, that few physicians would agree to precociously carry out the procedure and that feasibility is therefore low, assigning a weak strength of recommendation was decided.
Good clinical practice approach
Based on two CPGs recommendations 11, 12 , some subgroups of asymptomatic patients may be considered for early aortic valve replacement, due to the increased risk of mortality. Furthermore, consensus was reached on that patients with severe asymptomatic aortic stenosis should be evaluated every six months or when they experience symptoms related to the disease. In addition, it was deemed that when these patients develop symptoms, they should undergo valve replacement intervention. 
From evidence to decision
This question addresses the management of patients with severe symptomatic aortic stenosis. In these patients, SAVR or TAVR should be performed.
For this question, the following subpopulations were assessed: patients with low, intermediate and high surgical risk and inoperable patients. A patient is defined at low, intermediate and high surgical risk when he/she obtains values < 4, 4-8 and > 8%, respectively, on any of the proposed indexes (EuroSCORE II or STS) 12, 20, 27 . An inoperable patient is defined as that who has a preoperative mortality and morbidity risk > 50% at one year, with compromise of ≥ 3 major organs/systems that will not improve postoperatively, severe frailty or a severe hindrance to the specific procedure 28 .
In patients with low surgical risk, one SR 29 (2 RCTs and 4 observational studies, n = 3,484) found that TAVR, in comparison with SAVR, has similar all-cause 30 days and 1-year mortality, higher late mortality, lower risk of acute kidney injury, similar risk of stroke, higher risk for major vascular complications and need for permanent pacemaker implantation. Based on these heterogeneous results, and since TAVR was deemed to require greater use of resources, formulating a recommendation in favor of SAVR was decided. Given that the quality of evidence is low, and that patients and doctors do not entirely accept it, this recommendation had a weak strength.
In patients with intermediate surgical risk, the SRs by Singh 20 (3 RCTs and 5 observational studies, n = 4,752) and Sardar 27 (2 RCTs and 5 observational studies, n = 4,601) found that TAVR, in comparison with SAVR, has similar 30-day and 1-year all-cause mortality, similar stroke risk, similar myocardial infarction risk, lower acute kidney injury risk, lower major bleeding risk and greater need for permanent pacemaker implantation. Based on these heterogeneous results, in addition to the fact that the balance of benefits and risks of the intervention did not favor the use of TAVR, despite the fact that this intervention requires higher use of resources, formulating a recommendation in favor of SAVR was decided. Since the quality of evidence is low, it would not be entirely accepted by doctors and patients, which would hinder its feasibility; therefore, assigning weak strength to the recommendation was decided.
In patients with high surgical risk, the PARTNER 1 RCT (n = 699), with results published at one year 30 , three years 31 and five years of follow-up 32 , TAVR, in comparison SAVR, was found to have similar all-cause mortality at 30 days, one year, three and five years, higher risk of stroke, similar risk of transient ischemic attack, lower risk of acute kidney failure, similar risk of acute myocardial infarction, higher risk of major vascular complication and lower risk of major bleeding. Since the quality of evidence was low, and since doctors and patients would prefer TAVR, but owing to its low feasibility and excessive use of resources, formulating a weak recommendation for using any of the interventions (SAVR or TAVR) was decided. In inoperable patients but with life expectancy of more than one year, there are also results available from the PARTNER 1 RCT (n = 358), published at one 28 , two 33 , three 34 and five years of follow-up 24 ; TAVR was found to have lower all-cause mortality than medical treatment. Therefore, formulating a recommendation in favor of TAVR was decided. Given that the quality of evidence was moderate and that it would be accepted by both doctors and patients, this recommendation had a strong strength of recommendation.
Good clinical practice approach
-In patients with severe symptomatic aortic stenosis with life expectancy of more one year, it was agreed that performing aortic valve replacement should be sought in order to relieve symptoms and lessen mortality. In addition, in patients with life expectancy of less than one year, carrying out SAVR or TAVR was considered not to be justified 11, 24, 34 Team will evaluate each particular case to define the possible use of other approaches such as through the subclavian artery, or the transapical or transaortic routes. The Heart Team will make this decision based on invasive and/or non-invasive imaging studies. GCP.
From evidence to decision
Once TAVR performance has been decided, the access route for transcatheter aortic valve implantation should be established; the most common routes in our setting are: transfemoral (TF), through the subclavian artery (TSc) and transapical (TA).
To answer this question, two comparisons were assessed: TF vs. TSc and TF vs. TA. As for the comparison between TF and TSc, one SR (6 observational studies, n = 4,504) found that 30-day mortality, one-year mortality, major complications at 30 days and acute kidney injury were similar between both groups 37 . However, favoring the TF approach was decided because it is easier and more accepted by professionals.
Regarding the comparison between TF and TA, the SRs that were considered found that 30-day mortality 38 and acute kidney injury 39 were lower in the TF group, while vascular complications were higher in the TF group 40 ; and one-year mortality 40 , definitive pacemaker implantation and 30-day bleeding were similar in both groups 41 . Thirty-day mortality and acute kidney injury were considered to be the most clinically relevant outcomes and, hence, favoring the TF approach was decided.
Therefore, due to its benefits, and especially to a lower risk of complications, formulating a recommendation in favor of the use of the TF route was decided.
Given that the quality of evidence is very low, that the route of access for TAVR may depend on anatomical factors, and due to certain comorbidities, as well as to the fact that not all doctors and patients find always using this route of access acceptable, formulating a weak recommendation was decided.
Good clinical practice approach
If the TF approach cannot be performed, it was deemed that other approaches can be chosen, according to availability and training. This decision should be taken by the Heart Team based on invasive and/or non-invasive imaging studies.
Question 6. In patients with severe aortic stenosis in whom performing percutaneous aortic valve replacement is decided and who, in addition, have severe coronary artery disease, should percutaneous coronary intervention be performed?
Recommendations and good clinical practice points
-In patients with severe aortic stenosis in whom performing TAVR is decided and who, in addition, have severe coronary artery disease, we suggest performing percutaneous coronary intervention (PCI). Weak recommendation in favor, very low quality of evidence ⊕⊝⊝⊝. -In patients with severe aortic stenosis in whom performing TAVR is decided and who, in addition, have severe coronary artery disease for which performing PCI has been decided, we suggest that PCI should be carried out prior to TAVR. Weak recommendation in favor, very low quality of evidence ⊕⊝⊝⊝. -Performing myocardial revascularization (PCI for those undergoing TAVR or coronary artery bypass graft for those undergoing SAVR) is recommended when severe coronary artery disease is found (≥ 70% reduction in the diameter of any major coronary artery or ≥ 50% reduction in the diameter of the left coronary artery trunk). GCP.
From evidence to decision
Approximately half the patients with severe aortic stenosis have chronic coronary heart disease 6 . In patients who will undergo TAVR and that also have severe coronary disease, whether PCI is to be performed should be decided, and if so, whether it will be performed in advance or at the same moment (concomitant) than TAVR.
With regard to the decision to perform PCI or not, one SR (7 observational studies, n = 1,631) compared patients undergoing TAVR with PCI and undergoing TAVR without PCI, and found that 30-day, 6-month and one-year mortality, cardiovascular mortality, as well as vascular access site complications, were similar 42 . This evidence suggests that PCI for severe coronary disease might be carried out without major risks in these patients. Therefore, formulating a recommendation in favor of PCI performance was decided.
Regarding the decision on whether to perform PCI previously or concomitant with TAVR, one SR (7 observational studies, n = 1,631) that compared patients undergoing PCI prior and concomitant with TAVR, found that kidney failure incidence was higher in the concomitant group, whereas 30-day mortality and vascular access site complications were similar between groups 42 . In that same sense, an observational study (n = 65) found that mortality was similar between these groups 43 . Due to the lower risk of kidney failure and the complexity of performing PCI concomitant with TAVR in our context, formulating a recommendation in favor of the performance of PCI prior to TAVR was decided.
In view of the very low quality of evidence, regular acceptability by doctors and patients, and the low feasibility of performing this procedure, assigning a weak strength of recommendation was decided.
Good clinical practice approach
Adopting the AHA/ACC 2014 guidelines 44 GCP point on the need for perform myocardial revascularization (PCI for those undergoing TAVR or coronary artery bypass graft for those undergoing SAVR) in those patients with severe coronary artery disease (defined as ≥ 70% reduction in the diameter of any major coronary artery or ≥ 50% reduction in the diameter of the left coronary artery trunk) was considered pertinent. • One clinical cardiologist with experience in valvular pathology.
• One cardiologist expert in cardiovascular imaging.
• One interventional cardiologist.
• One cardiovascular surgeon with experience in valvular pathology. GCP.
From evidence to decision
The Heart Team is a multidisciplinary and collaborative team whose purpose is to make decisions about the treatment of patients with severe aortic stenosis with intermediate, high or prohibitive risk 45, 46 . In the performed search no studies were found that have assessed the Heart Team efficacy, which is why no recommendations were issued, but GCP points were established by consensus.
Good clinical practice approach
It was deemed that health establishments that carry out cardiac surgery in patients with severe aortic valve stenosis and that have high surgical risk need to decide between the performance of SAVR and TAVR 46 in the Heart Team. For the formation of the Heart Team, recommendations of other authors were considered 15,26,46-52 , as well as feasibility according to the local context. This way, it was established by consensus that the Heart Team should be comprised by at least: one clinical cardiologist with experience in valvular pathology, one cardiologist expert in cardiovascular imaging, one interventional cardiologist certified in TAVR and one cardiovascular surgeon with experience in valvular pathology.
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